MeSH tree: C19.246.300
The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, a study published by The BMJ finds. ...
57 minutes ago
0
0
Young women are leading a worrying increase in early-onset type 2 diabetes diagnoses in England, according to a new analysis. In a population study of type 2 diabetes in England, researchers found a clear generational divide, ...
8 hours ago
0
3
In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers predict that anticipated price reductions of up to 70% will dramatically increase both the cost-effectiveness ...
19 hours ago
0
4
Heart failure already affects more than 60 million people worldwide and is one of the leading causes of hospitalization among people 65 and older. Although it is commonly associated with advanced cardiovascular disease, it ...
22 hours ago
0
4
Use of newer GLP-1 receptor agonists (semaglutide or tirzepatide) for obesity or diabetes among people with alcohol use disorder was associated with a reduction in alcohol-related hospital admissions, according to a study ...
Jul 21, 2026
0
5
GLP-1 receptor agonists are among the active ingredients in so-called weight-loss injections. Originally developed to treat type 2 diabetes, they are now also used to treat severe obesity. In recent years, studies have provided ...
Jul 21, 2026
0
5
For many adults at risk of type 2 diabetes, knowing where to begin can be one of the biggest obstacles to prevention. A new study from the Healthy Hawaiʻi Evaluation Team (HHET) at the University of Hawaiʻi at Mānoa Thompson ...
Jul 21, 2026
0
3
A study by researchers at U.S. health insurance and medical services provider Kaiser Permanente, the Food is Medicine Institute at the Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy at Tufts University, ...
Jul 21, 2026
0
7
New research presented at the International Congress on Obesity (ICO2026), hosted by the World Obesity Federation (WOF) in Mexico City, Mexico, July 15–17, shows how various sectors representing the ultra-processed food (UPF) ...
Jul 20, 2026
0
12
Globally, the number of people with type 2 diabetes (T2D) is escalating. In Australia, Aboriginal and Torres Strait Islander peoples are four times as likely to die from T2D or experience serious T2D-related disease as non-Indigenous ...
Jul 20, 2026
0
2
